CASI Pharmaceuticals (NASDAQ:CASI) Shareholders Are Still up 129% Over 1 Year Despite Pulling Back 22% in the Past Week
Express News | CASI Pharmaceuticals Inc - Effective From Sept 10, Position of President of Co Was Removed
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Casi Pharmaceuticals Files to Sell 3M Ordinary Shares for Holders.
CASI Pharmaceuticals Shifts Focus, Garners Investment
CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | CASI Pharmaceuticals: Qtrly Shr Loss $0.52
Express News | CASI Pharmaceuticals Q2 Revenue USD 4 Million
Express News | CASI Pharmaceuticals Announces Second Quarter 2024 Business and Financial Results
CASI Pharmaceuticals 2Q Loss/Shr 52c >CASI
CASI Pharmaceuticals Freezes Juventas Assets Amid Dispute
Express News | CASI Pharmaceuticals Inc - CASI Pharmaceuticals Obtains Asset Freezing Order in Court of P.r. China Against Juventas
CASI Pharmaceuticals Welcomes New CFO
CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharmaceuticals Names Daniel Lang Chief Financial Officer >CASI
Express News | CASI Pharmaceuticals Announces Appointment of Daniel Lang, Md as CFO and Svp
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
Express News | CASI Pharmaceuticals Shares Are Trading Higher After the Company Announced Plans to Submit an Investigational New Drug Application to the FDA for CID-103 for the Treatment of Antibody-mediated Rejection in Kidney Transplant Recipients.
Market-Moving News for June 27th
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data